NASDAQ: PGEN
Precigen, Inc.
Healthcare · Biotechnology
Market Cap
$1.25B
52w High
$5.47
52w Low
$1.26
P/E
-6.13
Volume
2.43M
Outstanding Shares
300.43M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 207.41% over the last year. Revenue grew 652.08% over the trailing twelve months. Operating margin moved from -3,171.03% to -278.24%. Free cash flow declined 55.87% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (78th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -278.24% — continued expansion would be needed to justify the premium. Revenue growth of 652.08% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
11
Buy
4
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.02 · Revenue est $26.16M
View